Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?

被引:13
|
作者
Yang, Shenmiao [1 ]
Gale, Robert Peter [2 ]
Shi, Hongxia [1 ]
Liu, Yanrong [1 ]
Lai, Yueyun [1 ]
Lu, Jin [1 ]
Huang, Xiaojun [1 ,3 ]
机构
[1] Peking Univ, Inst Hematol, Peoples Hosp, Xizhimen Nan St 11, Beijing 100044, Peoples R China
[2] Imperial Coll London, Haematol Res Ctr, Dept Med, Div Expt Med, London SW7 2AZ, England
[3] Peking Univ, Acad Adv Interdisciplinary Studies, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
关键词
Chronic lymphocytic leukaemia; Incidence; Asia; NON-HODGKIN-LYMPHOMA; RISK-FACTORS; ASIANS; NEOPLASMS; SURVIVORS; SHANGHAI; US;
D O I
10.1016/j.leukres.2018.08.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Chronic lymphocytic leukaemia (CLL) is 10- to 20-fold less common in Asians (including Han Chinese) compared with persons of predominately European descent. Why is unknown but seems predominately genetic. We observed an increasing frequency of new cases of CLL at our Haematology Centre beginning 2011 and wondered why. Objective: Determine the cause(s) for this increased frequency. Method: We interrogated the context of CLL diagnosis in 483 consecutive subjects seen at the Institute of Haematology of a large referral hospital in Beijing. 3 cohorts were considered based on why a CBC was done to establish the CLL diagnosis: (1) a CBC-testing situation unrelated to a health condition such as a routine annual health exam or application for employment or medical insurance (termed routine CBC); (2) an unrelated medical condition such as a cold, influenza, heart disease etc. (termed CBC for other disorders); and (3) signs and/or symptoms consistent with CLL such as lymph-adenopathy, hepato- or splenomegaly, fatigue, B-symptoms etc. (termed CBC for possible CLL). Results: Data regarding context of CLL diagnosis were available for 389 subjects (81%). Proportions of subjects in the 3 cohorts were 44% (95% confidence interval [CI]; 39, 49%), 24% (20, 28%) and 32% (28, 37%). The proportion of subjects whose evaluation of CLL was prompted by an abnormal CBC not for possible CLL (cohorts 1 and 2) increased over the surveillance interval (r = 0.164; P = 0.001) as did median age at diagnosis (r = 0.207; P < 0.001). Age at diagnosis was correlated with probability of CLL being suspected because of an abnormal routine CBC (r = 0.249; P < 0.001); 42% (32, 53%) amongst subjects <= 50 years versus 86% (75, 92%; P < 0.001) among those > 70 years. Consistent with this, older subjects were diagnosed at Rai stage-0 with asymptomatic disease compared with younger subjects (P < 0.001). Conclusion: Our data suggest much of the increased frequency of CLL at our centre and likely elsewhere in China predominately reflects ascertainment bias. Other variables may also operate.
引用
收藏
页码:16 / 20
页数:5
相关论文
共 50 条
  • [21] Correlation between hypogammaglobulinaemia, infections and mortality in chronic lymphocytic leukaemia (CLL)
    Losonczy, H.
    Nagy, A.
    Kosztolanyi, S.
    Csalodi, R.
    Toth, O.
    Alizadeh, H.
    Szomor, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 173 - 174
  • [22] Thermal sensitivity and osmotic lysability of chronic lymphocytic leukaemia (CLL) cells
    Sivakumaran, M
    Zaidi, Y
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 200 - 200
  • [23] Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia
    Kuss, Bryone J.
    Tam, Constantine S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 5 - 10
  • [24] Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)
    Zenz, Thorsten
    Froehling, Stefan
    Mertens, Daniel
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (01) : 71 - 84
  • [25] Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)
    Lim, Yeong Jer
    Duckworth, Andrew
    Clarke, Kim
    Oates, Melanie
    Gornall, Matthew
    Kalakonda, Nagesh
    Slupsky, Joseph
    Pettitt, Andrew
    BLOOD, 2023, 142
  • [26] SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)
    Philippen, Angela
    Diener, Susanne
    Zenz, Thorsten
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Mertens, Daniel
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (05) : 633 - 636
  • [27] Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL).
    Lane, SW
    Mollee, PN
    Bird, R
    Porceddu, S
    Gill, D
    BLOOD, 2005, 106 (11) : 329B - 329B
  • [28] A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia
    Paul, Shilpa
    Jain, Nitin
    Ferrajoli, Alessandra
    O'Brien, Susan
    Burger, Jan
    Keating, Michael
    Wierda, William
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 606 - 608
  • [29] PREVALENCE AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN GERMANY: AN ANALYSIS OF SICKNESS FUNDS
    Tomeczkowski, J.
    Leisten, M. K.
    Metin, H.
    Khuen, C.
    Fleischmann, J.
    Tapprich, C.
    VALUE IN HEALTH, 2014, 17 (07) : A524 - A524
  • [30] Acquired factor X (FX) deficiency, chronic lymphocytic leukaemia (CLL) and amyloidosis (A)
    Bastos, L. A.
    Grosso, S. H.
    Ingratti, M.
    Luceros, Sanchez A.
    Rey, I
    Rodriguez, A.
    Meschengieser, S.
    Blanco, A.
    Lazzari, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1195 - 1195